CAS: 3614-30-0; 4,4-Diphenylbutan-2-Yl-Ethyl-Dimethylazanium,Bromide

📜(S)-Recipavrin,溴乙烷 反应生成 依美溴铵
参考文献:Aasen,Arne Jzhustorgen;Ssnjelderur,Lise,Acta Chem. Scand.,42,(1988) N 3,206-210
标题:Aasen,Arne Jzhustorgen;Ssnjelderur,Lise,Acta Chem. Scand.,42,(1988) N 3,206-210

专利信息

专利号:US-8293290-B2
优先权日:2003-04-08
标题:Annatto extract compositions, including geranyl geraniols and methods of use
发明人：TAN BARRIE
权利人:TAN BARRIE; AMERICAN RIVER NUTRITION INC
摘要:Annatto extract composition (AEC), including cis and trans geranyl geraniols (GG) and tocopherol-free C-5 unsubstituted tocotrienols (T3), increases the de novo synthesis of intermediate isoprenoid and distal protein products, including endogenous coenzyme Q10 (CoQ10), dolichols (DL) and all subsequent GG-prenylated and DL-glycosylated proteins, including GG-porphyrinated hemes. This intermediate and distal product replenishment by AEC reverses maladies of myotoxicity (of both drug and non-drug origins), including maladies that affect the muscle, kidney, eye, GI tract and skin, nerve, blood, and CoQ10-related syndromes of energetics and LDL protection. AEC anabolically increases the endogenous de novo CoQ10 synthesis via GG elongation/prenylation of side-chain and conversely CoQ10 catabolically increases the endogenous de novo GG synthesis via beta-oxidation of CoQ10. Also, such AEC decreases de novo synthesis and increases disposal of triglycerides (TG) in humans via PPAR activation and SREBP deactivation. Such drop in TG by AEC reverses maladies of insulin resistance (IR) and metabolic syndrome (MS), prediabetes, diabetes and diabetes-related cardiovascular diseases (CVD). GG activates PPAR and down regulates SREBP transcription factors. This AEC, containing GG, inhibits cancer growth whether or not GG involvement in protein prenylation is required.

专利号:US-7993390-B2
优先权日:2002-02-08
标 题:Implantable or insertable medical device resistant to microbial growth and biofilm formation
发明人：MILLER KATHLEEN M; BUCAY-COUTO WEENNA; LI JIANMIN
权利人:BOSTON SCIENT SCIMED INC
摘要:Disclosed are implantable or insertable medical devices that provide resistance to microbial growth on and in the environment of the device and resistance to microbial adhesion and biofilm formation on the device. In particular, the invention discloses implantable or insertable medical devices that comprise at least one biocompatible matrix polymer region, an antimicrobial agent for providing resistance to microbial growth and/or a microbial adhesion/biofilm synthesis inhibitor for inhibiting the attachment of microbes and the synthesis and accumulation of biofilm on the surface of the medical device. Also disclosed are methods of manufacturing such devices under conditions that substantially prevent preferential partitioning of any of said bioactive agents to a surface of the biocompatible matrix polymer and substantially prevent chemical modification of said bioactive agents.